Cargando…
Guiding model‐driven combination dose selection using multi‐objective synergy optimization
Despite the growing appreciation that the future of cancer treatment lies in combination therapies, finding the right drugs to combine and the optimal way to combine them remains a nontrivial task. Herein, we introduce the Multi‐Objective Optimization of Combination Synergy – Dose Selection (MOOCS‐D...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681518/ https://www.ncbi.nlm.nih.gov/pubmed/37415306 http://dx.doi.org/10.1002/psp4.12997 |
_version_ | 1785142553839927296 |
---|---|
author | Gevertz, Jana L. Kareva, Irina |
author_facet | Gevertz, Jana L. Kareva, Irina |
author_sort | Gevertz, Jana L. |
collection | PubMed |
description | Despite the growing appreciation that the future of cancer treatment lies in combination therapies, finding the right drugs to combine and the optimal way to combine them remains a nontrivial task. Herein, we introduce the Multi‐Objective Optimization of Combination Synergy – Dose Selection (MOOCS‐DS) method for using drug synergy as a tool for guiding dose selection for a combination of preselected compounds. This method decouples synergy of potency (SoP) and synergy of efficacy (SoE) and identifies Pareto optimal solutions in a multi‐objective synergy space. Using a toy combination therapy model, we explore properties of the MOOCS‐DS algorithm, including how optimal dose selection can be influenced by the metric used to define SoP and SoE. We also demonstrate the potential of our approach to guide dose and schedule selection using a model fit to preclinical data of the combination of the PD‐1 checkpoint inhibitor pembrolizumab and the anti‐angiogenic drug bevacizumab on two lung cancer cell lines. The identification of optimally synergistic combination doses has the potential to inform preclinical experimental design and improve the success rates of combination therapies. Jel classificationDose Finding in Oncology |
format | Online Article Text |
id | pubmed-10681518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106815182023-07-06 Guiding model‐driven combination dose selection using multi‐objective synergy optimization Gevertz, Jana L. Kareva, Irina CPT Pharmacometrics Syst Pharmacol Research Despite the growing appreciation that the future of cancer treatment lies in combination therapies, finding the right drugs to combine and the optimal way to combine them remains a nontrivial task. Herein, we introduce the Multi‐Objective Optimization of Combination Synergy – Dose Selection (MOOCS‐DS) method for using drug synergy as a tool for guiding dose selection for a combination of preselected compounds. This method decouples synergy of potency (SoP) and synergy of efficacy (SoE) and identifies Pareto optimal solutions in a multi‐objective synergy space. Using a toy combination therapy model, we explore properties of the MOOCS‐DS algorithm, including how optimal dose selection can be influenced by the metric used to define SoP and SoE. We also demonstrate the potential of our approach to guide dose and schedule selection using a model fit to preclinical data of the combination of the PD‐1 checkpoint inhibitor pembrolizumab and the anti‐angiogenic drug bevacizumab on two lung cancer cell lines. The identification of optimally synergistic combination doses has the potential to inform preclinical experimental design and improve the success rates of combination therapies. Jel classificationDose Finding in Oncology John Wiley and Sons Inc. 2023-07-06 /pmc/articles/PMC10681518/ /pubmed/37415306 http://dx.doi.org/10.1002/psp4.12997 Text en © 2023 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Gevertz, Jana L. Kareva, Irina Guiding model‐driven combination dose selection using multi‐objective synergy optimization |
title | Guiding model‐driven combination dose selection using multi‐objective synergy optimization |
title_full | Guiding model‐driven combination dose selection using multi‐objective synergy optimization |
title_fullStr | Guiding model‐driven combination dose selection using multi‐objective synergy optimization |
title_full_unstemmed | Guiding model‐driven combination dose selection using multi‐objective synergy optimization |
title_short | Guiding model‐driven combination dose selection using multi‐objective synergy optimization |
title_sort | guiding model‐driven combination dose selection using multi‐objective synergy optimization |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681518/ https://www.ncbi.nlm.nih.gov/pubmed/37415306 http://dx.doi.org/10.1002/psp4.12997 |
work_keys_str_mv | AT gevertzjanal guidingmodeldrivencombinationdoseselectionusingmultiobjectivesynergyoptimization AT karevairina guidingmodeldrivencombinationdoseselectionusingmultiobjectivesynergyoptimization |